Rodolphe Barrangou
Directeur/Membre du Conseil chez Ancilia Biosciences, Inc.
Postes actifs de Rodolphe Barrangou
Sociétés | Poste | Début | Fin |
---|---|---|---|
Ancilia Biosciences, Inc.
Ancilia Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Ancilia Biosciences, Inc. is an American company that is developing virus-resistant live bacterial biotherapeutics to alter the gut microbiome and treat disease. Ancilia is based in the United States, and its founders and advisers include key scientific leaders across CRISPR and the virome. Ancilia's proprietary platform is being developed as an essential enabling technology that characterizes viral phages and leverages the natural function of CRISPR to produce a new class of live biotherapeutics with engineered immunity to key viral pathogens. The company has demonstrated proof of principle and filed key patents for the technology. The company was founded to overcome a potential obstacle to the success of LBPs, which is their failure to address the role of predatory viral phages in causing disease and limiting the ability of LBPs to engraft in the gut. The company was founded by Alexandra Sakatos, who has been the CEO since incorporation. | Directeur-Opérations de Back Office | - | - |
Directeur/Membre du Conseil | - | - |
Historique de carrière de Rodolphe Barrangou
Anciens postes connus de Rodolphe Barrangou
Sociétés | Poste | Début | Fin |
---|---|---|---|
CARIBOU BIOSCIENCES, INC. | Président | - | - |
Locus Biosciences, Inc.
Locus Biosciences, Inc. Packaged SoftwareTechnology Services Locus Biosciences, Inc. develops CRISPR-engineered precision antibacterial products for antibiotic-resistant bacterial infections and microbiome-related disease. The firm offers CRISPR-engineered bacteriophage and CRISPR-Cas3 phage. The company was founded by Charles Gersbach, Dave Ousterout, Chase Beisel, Paul M. Garofolo, Nick Taylor, and Rodolphe Barrangou in 2015 and is headquartered in Morrisville, NC. | Fondateur | 01/01/2015 | - |
INTELLIA THERAPEUTICS, INC. | Fondateur | 01/05/2014 | - |
Formation de Rodolphe Barrangou
North Carolina State University | Doctorate Degree |
University of Wisconsin | Masters Business Admin |
Université de Technologie de Compiègne | Graduate Degree |
Statistiques
Internationale
Etats-Unis | 7 |
France | 3 |
Opérationnelle
Founder | 2 |
Graduate Degree | 2 |
Chairman | 1 |
Sectorielle
Consumer Services | 5 |
Health Technology | 3 |
Technology Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
INTELLIA THERAPEUTICS, INC. | Health Technology |
CARIBOU BIOSCIENCES, INC. | Health Technology |
Entreprise privées | 3 |
---|---|
Université de Paris 5 René Descartes | Consumer Services |
Locus Biosciences, Inc.
Locus Biosciences, Inc. Packaged SoftwareTechnology Services Locus Biosciences, Inc. develops CRISPR-engineered precision antibacterial products for antibiotic-resistant bacterial infections and microbiome-related disease. The firm offers CRISPR-engineered bacteriophage and CRISPR-Cas3 phage. The company was founded by Charles Gersbach, Dave Ousterout, Chase Beisel, Paul M. Garofolo, Nick Taylor, and Rodolphe Barrangou in 2015 and is headquartered in Morrisville, NC. | Technology Services |
Ancilia Biosciences, Inc.
Ancilia Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Ancilia Biosciences, Inc. is an American company that is developing virus-resistant live bacterial biotherapeutics to alter the gut microbiome and treat disease. Ancilia is based in the United States, and its founders and advisers include key scientific leaders across CRISPR and the virome. Ancilia's proprietary platform is being developed as an essential enabling technology that characterizes viral phages and leverages the natural function of CRISPR to produce a new class of live biotherapeutics with engineered immunity to key viral pathogens. The company has demonstrated proof of principle and filed key patents for the technology. The company was founded to overcome a potential obstacle to the success of LBPs, which is their failure to address the role of predatory viral phages in causing disease and limiting the ability of LBPs to engraft in the gut. The company was founded by Alexandra Sakatos, who has been the CEO since incorporation. | Commercial Services |
- Bourse
- Insiders
- Rodolphe Barrangou
- Expérience